BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/15/2018 1:34:32 PM | Browse: 1095 | Download: 1452
 |
Received |
|
2018-08-06 07:16 |
|
Peer-Review Started |
|
2018-08-07 01:05 |
|
To Make the First Decision |
|
2018-09-03 01:13 |
|
Return for Revision |
|
2018-09-03 09:07 |
|
Revised |
|
2018-09-07 08:30 |
|
Second Decision |
|
2018-09-12 10:43 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-10-10 13:43 |
|
Articles in Press |
|
2018-10-10 13:43 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2018-10-27 16:20 |
|
Typeset the Manuscript |
|
2018-11-13 03:32 |
|
Publish the Manuscript Online |
|
2018-11-15 13:34 |
| ISSN |
1948-5204 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Huapyong Kang, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song and Jeong Youp Park |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jeong Youp Park, MD, PhD, Associate Professor, Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1, Yonsei-Ro, Seodaemun-Gu, Seoul 03722, South Korea. sensass@yuhs.ac |
| Key Words |
Dose modification; Adverse event; Pancreatic cancer; Adenocarcinoma; FOLFIRINOX; Chemotherapy |
| Core Tip |
Although the efficacy of FOLFIRINOX for pancreatic cancer has been well demonstrated, its relatively high toxicity rate is an important concern. We aimed to directly compare the efficacy and toxicity of standard-dose FOLFIRINOX and modified-dose FOLFIRINOX (mFOLFIRINOX, 75% of standard-dose) for pancreatic cancer. One hundred and thirty patients with pancreatic cancer (standard: 88 vs modified: 42) were reviewed retrospectively. Response rates, progression-free survival, and overall survival were not different between both groups. However, severe adverse events such as neutropenia, anorexia and diarrhea were significantly lower in the mFOLFIRINOX group. If clinically necessary, initiating FOLFIRINOX with 75% of the standard-dose can alleviate toxicity concerns without compromising efficacy. |
| Publish Date |
2018-11-15 13:34 |
| Citation |
Kang H, Jo JH, Lee HS, Chung MJ, Bang S, Park SW, Song SY, Park JY. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. World J Gastrointest Oncol 2018; 10(11): 421-430 |
| URL |
http://www.wjgnet.com/1948-5204/full/v10/i11/421.htm |
| DOI |
http://dx.doi.org/10.4251/wjgo.v10.i11.421 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
